Sanofi sues Novo over 'misleading' Tresiba marketing materials
Sanofi has sued Novo over the Danish drugmaker’s marketing materials for Tresiba, alleging that they falsely claimed Sanofi’s competing products—blockbuster Lantus and follow-up Toujeo—won’t be available to many U.S. patients down the line. The pharma giant is seeking an order to force Novo to pay unspecified money damages and pull the materials in question. According to Sanofi’s complaint, filed in U.S. District Court for the District of New Jersey, the materials urged doctors and patients to make the change in treatment because Sanofi’s meds would supposedly be “blocked” in January.
Acquisitive Allergan g...
